Key strategies include abnormal activation of immune checkpoints, where tumor cells overexpress immune checkpoint molecules such as PD‐L1, binding to PD‐1 receptors on T cells to inhibit their activation and cytotoxic function [336]. The gene discussed is CD274; the disease is neoplasm.